reported that HDAC inhibitor panobinostat could control transcriptionally the expression of MYD88 and synergize with ibrutinib in ABC-DLBCL cell lines with MYD88 mutattion (124). This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.